# Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer

> **NCT06970353** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 40 (estimated)

## Conditions studied

- Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation
- Advanced PDTC or ATC With NRAS Mutation

## Interventions

- **DRUG:** Tunlametinib
- **DRUG:** Tunlametinib+PD-1 mAb

## Key facts

- **NCT ID:** NCT06970353
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-27
- **Primary completion:** 2026-12-30
- **Final completion:** 2031-12-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06970353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06970353, "Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06970353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*